LITTLE FALLS, N.J., Feb. 27 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today that the FDA has cleared its Medivators Advantage Plus Endoscope Reprocessing System and new Rapicide(R) PA High Level Disinfectant for sale in the United States. The Advantage Plus System, with its accompanying new chemistry, represents the latest in a long line of "state of the art", innovative reprocessing technologies that Medivators has been delivering to hospitals and stand-alone GI centers for over 20 years.
Andrew Krakauer, Cantel Medical's President stated, "We are very pleased to have broadened our regulatory approvals and can now sell the full Advantage Series in the United States. The Advantage Plus, together with its environmentally friendly Rapicide PA chemistry, brings a new, fully integrated and compliant dimension to busy endoscopy centers and is now available worldwide. We believe that this system should rapidly become the new standard of excellence for safety and efficacy, as well as user friendly operation."
Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
|SOURCE Cantel Medical Corp.|
Copyright©2009 PR Newswire.
All rights reserved